Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SEC Investigates Elan Over Disclosures of Clinical Trial Data and Side Effect Reports

This article was originally published in The Pink Sheet Daily

Executive Summary

At issue: July 2008 reports of PML cases linked to Tysabri and key trial data for its Alzheimer's medication; Wyeth also gets a subpoena.

You may also be interested in...



Elan Says It Has Fixed The Biogen Breach, And Gives J&J a $115 Million Discount

The three-way drama heads toward a resolution -- if Biogen Idec accepts Elan's moves.

Judge Says Elan's J&J Deal Violates Tysabri Contract, Handing Biogen A Victory

Biogen Idec's lawyers took heat all day Thursday from a federal judge, but in the end she ruled in their favor. Now, Elan has 23 days to fix the breach.

Wyeth’s Pipeline Star Bapineuzumab Looks More Long Shot Than Sure Bet

Following the release of lackluster Phase II efficacy data on bapineuzumab in Alzheimer’s disease patients, talk of Wyeth as a takeover target resurfaces.

Topics

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel